¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º [~&C6pR  
_ED,DM  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ - VK 6Fq  
8?qEv,W  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ucm 3'j  
hK=\O)  
1. ICAM-1 <0[{Tn  
*SkUkqP9z  
2. interleukin 12(IL-12) e'<pw^I\  
Y.$InQ gL  
3. tumor infiltrating lymphocyte a/@<KnT  
ZdQm& ?  
4. TCR/CD3 complex 5ug?'TOj'  
|_l\.  
5. hematopoietin receptor family Qy ; M:q  
1j*I`xZ  
6. individual idiotype(IdI) B`Q.<Lqu  
o l 67x  
7. integrin # k+Gg w  
{8M=[4_`l  
8. colony-stimulatory factor (CSF) myH:bc>6  
dfB#+wh  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© %UJ!(_  
`Rj<qz^7  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? Kb0O auW  
s~$kzEtjjU  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ qE6:`f  
8 ?' ]W\)  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠhCO*gtA)M  
'l\V{0;mp  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ {+f@7^/i.  
<\x/Y$jm0n  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) bG +p  
lj.z>  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ ]}9cOb%I  
oaI7j=Gp  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR)  ,[ +  
(c(c MC'  
3. immunoglobulin superfamily (IgSF) 9>psQ0IRvr  
GFvZdP`s4  
4. selectin KtHh--j`  
D0PP   
5. anti-idiotypic antibody (¦ÁId)  D@qq=M  
j._9;HifZ  
6. major histocompatibility complex(MHC) >82Q!HaH  
TEB%y9  
7. immunotolerance r4NI(\gU  
N;D (_:^  
8. biological reponse modifier(BRM) {AIP\  
{i^ ?XdM  
9. immune reponse gene (Ir gene) =b,$jCv<,5  
L3nHvKA]  
10. reshaped antibody (or reconstituted antibody) Pf)<6?T  
u4$d#0sA  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© i[d-n/)  
n_v c}ame  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£  'm}~  
60~{sk~E  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? NNutpA}s  
=DE5 Wq19  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ @Qruc\_  
O:r<es1  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? / c/!13|  
\R&`bAdk  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ aChY5R  
ReKnvF~  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? VbBZ\`b  
XPUH\I=  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ sPkT>q  
!Si ZA"  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ .d8) *  
3dadeu^{A  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? /J{P8=x}_:  
4,H}'@Db}  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ f=~@e#U  
*PL+)2ob  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ:  +tfmBZl^  
b^Rg_,s  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ?3KI}'}EM  
Wf: AMxDm  
ÃâÒßѧ ( }JX ]-  
pPQ]#v  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 2Y  6/,W  
JEJ] '3  
1. CD8 Bu!Gy8\  
dP )8T  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 4 D\_[(P  
4 I y\   
3. immunoglobulin fold(Ig fold) 'ARQ7 Q[`  
J=4S\0Z*  
4. cadherin (Ca-dependent cell adhesion moleculers) y"@~5e477$  
]BAF  
5. idiotype-anti-idiotypic antibody immune network theory 8(Z*Vz uu  
;'gzR C  
6. HLA class II antigen !7%L%~z^  
zT_{M qY  
7. complementarity-determining region (CDR) 'Iu$4xo`[  
/-BplU*"9  
8. perforin(or pore-forming protein ,PFP) i"w$D{N  
NRoi` IIj  
9. high affinity IL-2 receptor deeOtco$LT  
^{~y+1lt'  
10. artificial active immunization lfj>]om$  
Iupk+x>  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© h ?p^DPo  
Q`19YX  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ5vP*oD  
2^qY, dL  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 CH9#<?l  
|n6nRE wW  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ rm"bplLZA  
{mkYW-4Se  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 9.%{M#j  
YToRG7X#  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ y@_4OkR@  
~^VcTSY@<L  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 1Z`<HW"  
Ko -<4wu  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ }"xC1<]  
[ 8v)\lu  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 4H1s"mP<  
@~a52'\  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ J@yy2AZnO  
=|?w<qc  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ADHe! [6q  
^(&:=r.PC  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© tk, H vE  
pK$^@~DE  
1. immunoglobulin gene rearrangement ;%U`lE0  
]`:Fj|>  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) dd$\Q  
BJlF@F#  
3. flow cytometry(FCM) Q$RP2&  
rVf`wJ6b  
4. carrier effect L!e@T'  
[& hdyLt  
5. positive selection of T lymphocytes in thymus LU%g>?m.]  
%*r P d>*  
6. mouse TH1(Th1) and TH2(Th2) subsets o.j;dsZ  
rg\|-_.es'  
7. perforin (pore-forming protein ,PFP) LFh(. }  
^&Qaf:M  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 2@A7i<p  
o]k[l ;  
9. SH-2(src-homology region 2) d5u ,x.R  
D{G#|&;  
10. Ab2¦Â (internal image) ]n!pn#Q  
Wc+ e>*  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© y6G[-?"/Q  
cvc.-7IO  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ,',fO?Qv'  
^TB%| yZ _  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? eQYW>z'%,  
t,RR\ S  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ67f#Z&r2k  
tp0^%!*9  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ EI/_=.d  
LR`/pet  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ<hS >L1ZSr  
3 vE;s"/  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ;1F3.ibE  
z+wBZn{0I  
ÃâÒßѧרҵ£º {L.0jAwB  
,!Ah+x  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ *UEo&B2+  
Ak|j J  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 9/Q5(P  
K4oLb"gB1  
´«È¾²¡Ñ§×¨Òµ£º CJ%7M`zy  
Hh;7 hY\  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ucB<  
6B|IbQ^  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ !9V_U  
=X>?Y,   
Ïû»¯×¨Òµ£º @XB/9!  
wYS 4#7  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ l$.C40v  
n802!d+Tn  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? @u$4{sjgf\  
Qv[@ioc  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 8+ Hho@=  
QiB:K Pz[  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 6(X(f;MEl  
s6!aGZ  
1. Fas(CD95)/FasL >5)$Qtz#  
F8/4PB8-  
2. common chain of cytokine receptor \$GlB+ iCx  
}!5"EL(L80  
3 . TCR/CD3 complex m$0T"`AP`  
bi[vs|  
4. negaive selection of thymocytes *G2p;n=2  
BW z*!(   
5. artificial active immune >*k3D&  
So,EPB+  
6. anti-idiotypic jD'\\jAUdm  
;S2^f;q~$  
7. IgSF Ws.F=kS>h  
(4x`/  
8. Integrin CGny#Vh  
c9r, <TR9  
9. chemokine bp;b;f>  
^JJ*pT:  
10. B7/CD28 *8t_$<'dQ  
fPa FL}&  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© Mp}aJzmkB;  
,o*x\jrGw  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ ~UEft  
gb( a`  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ Ae;> @k/|=  
ENr\+{{%  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 5@F1E8T  
Pur~Rz\ \  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ +MvcW.W~  
^fQ ]>/u  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ pmv;M`_|R  
N/4`afiV.  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ sy0|=E*;8"  
Akb#1Ww4  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ~C\R!DN,  
Oc}4`?oy<O  
1. B7/CD28 j;WZ[g#t  
LK-2e$1  
2. Th1 subset -iLp3m<ai  
fb0i6RC~&  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© V\5ZRLawP  
AvfSR p  
4. antibody affinity maturation u!S^lV@  
U%.O H?;f  
5. AP-1 _lcx?IV  
UFr ]$m&  
6. single chain variable fragment£¨ScFv£© 4^/MDM@  
nd_+g2x'  
7. NK cell receptor ixm-wZI  
E4idEQ}H  
8. Zinkernagel-Doherty phenomenon c5Fl:=h  
OE[ | 1?3  
9. Ig fold %#kml{I   
<]1Z  
10. CD40/CD40L 0' j/ 9vm  
]06orBV  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© %xv }  
oM ey^]!  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ b/"&E'5-`\  
i286 J.  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ Esx"nex  
E "9`  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ %+gK5aVab  
nbd-f6F6  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ W@S> #3,  
0G?*i_u\  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Q1hHK'3w  
P?WS=w*O0  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ F{,<6/ayRz  
)c432).Z  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ gu:8+/W8L  
X"hdCY%  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© )DG>omCY  
A?)nLp&Y  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ZRCm'p3  
4zo^ b0v  
1.Co-stimulators (or co-stimulating molecules) ;YGCsLT<xt  
*.F^`]yz  
2.NK-kB WlJ=X$  
OS - Xh-:z  
3.Immunoglobulin superfamily E!Ljq3iT`  
fGtYvl O-5  
4.antigen-presenting cell (APC) r%=}e++^%  
ue8"_N  
5.death domain Mn> /\e  
.Tm m  
6.CCR and CXCR Nv[MU@Tv  
GBg~NkC7.  
7.Lectin (or mitogen) KA#P_e{<@  
\img   
8.Clusters of differentiation, CD) U\'HB.P \  
](@HPAG]  
9.B7 family #lDW?  
[aS<u`/g|  
10.Cytotoxic T lymphocyte, CTL) ,%=SO 82W  
T%Nm  
11.IL-15 and IL-15 receptor (IL-15R) d!P3<:+R[  
KkJrh@lk  
12.MHC restriction '$q=r x  
:5W8S6[o  
13.Affinity-chromatography G(; hJ'LT  
}mdk+IEt  
14.Cyctosprin A, CsA '_~qAx@F#c  
6k9cvMs%H  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) &l8eljg  
1Qk]?R/DN  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© [C^&iLX/F*  
*,FU*zi  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ]#sF pWI[N  
/?Y]wY  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ;@<Rh^g]  
AW <"3 !@  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ M 8NWQ^Y  
=THRy ZCH  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Dbg,|UH  
:B7dxE9[r  
ÃâÒßѧרҵ£º /6{P ?)]pE  
Y/<`C  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ K6EG"Vv !  
}bZb8hiG  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ?#~km0~F)  
aoHAB <.C  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ .%G>z"Xx  
<~teD[1k"  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 5ktFL<^5T  
^xX1G _{  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) ,(3oAj\  
XGb*LY+Db6  
1. ADCC(antibody dependent cell-mediated cytotoxicity) {!&^VXZIT  
Y(&rlL(sPK  
2. »·æß¾úËØ(cyclosporin) _;mA(j  
b6NGhkr'\  
3. KIR(killer cell inhibitory receptor) $d*PY_  
;_ S D W  
4. HLDA(human leucocyte differentiation antigen) |,Kk#`lW<f  
~%L=<TBAc  
5. Interleukin 18(IL-18) ] ^53Qbrv  
0uu)0:  
6. ÕûºÏËØ(integrin) 3Z}v%=5 "  
6~OJB!  
7. Fas/FasL ~e _  
pIHpjx  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) FQ"ED:lks  
ye-[l7  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) SUDvKP  
VG_xNM  
10. Th1/Th2 BtrMv6  
22/"0=2g  
11. »ùÒòÒßÃç(DNAÒßÃç) UPy 4ST  
!l5@L\   
12. chemokines and chemokine receptor y~'%PUN  
d&lT/S  
13. ÃâÒßÄÍÊÜ J1w,;T\55  
y&V%xE/  
14. ¹²´Ì¼¤·Ö×Ó Bbtc[@"X  
&b'{3o_KN  
15. ËÀÍö½á¹¹Óò(death domain) N;a'`l  
n lZJ}xZ  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) Wuk!\<T{  
L2c\i  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? r4ljA@L  
{55f{5y3 c  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ"xNP"S  
TK0WfWch  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 'nS>'yYH#  
fWf't2H&  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ Y$#6%`*#>n  
3:)_oHq  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Re s4;C  
6E2#VT>@/  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ T oT('  
9e4`N"#,lI  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) \;iOQqv0&  
)%<,JD  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 4|4 *rhwp  
,g4T>7`&U%  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ EnmMFxu<  
`(DHa=s1  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»